Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APHRODITE Group 3: r-hFSH-alfa and hCG in men with oligozoospermia and low testosterone
2025-525005-20-00Phase 4Authorised
- Sponsor
- Martin Luther University Halle-Wittenberg
- Start
- May 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 4, randomised trial of follitropin alfa and human chorionic gonadotropin in male infertility, oligospermia and Hypogonadism (2 arms), sponsored by Martin Luther University Halle-Wittenberg. Primary endpoint: Change in sperm concentration at week 16 vs untreated arm. Planned start May 2026; status: authorised.
02
Drugs
follitropin alfahuman chorionic gonadotropin
03
Conditions
male infertilityoligospermiaHypogonadism
Beyond the preview
Go deeper on 2025-525005-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-525005-20-00.